Question explored with the scientific record
Is it possible to come off and how after using Clozapine for 25+ years
The short version: after 25 years on clozapine, coming off carries a real risk of severe relapse, and the evidence on how to do it safely is thin.
The evidence we have is a mixed bag. A 2018 clinical note described six men who had been on clozapine for 4 to 14 years and tried to reduce or stop it [1]. Some saw short-term improvements in side effects, but others had worsening psychosis that required going back on the drug or adding another antipsychotic. That is a tiny sample, not a protocol. A much larger 2021 South Korean study of over 44,000 first-episode patients found that clozapine had the lowest risk of psychiatric hospitalization compared to no treatment at all [3]. That tells you the drug works for keeping people out of the hospital, but it does not tell you what happens after 25 years of use, or how to stop.
The mechanism that makes coming off dangerous is well-documented outside this retrieval. Long-term antipsychotic use causes dopamine supersensitivity: the brain adapts to the drug by making its dopamine receptors more sensitive, so when the drug is removed, the system can swing into overdrive and trigger a psychosis that is worse than the original illness [6]. This is not a theory; it is a known pharmacological consequence. The longer you have been on the drug, the more likely this is. After 25 years, the risk is substantial.
There is no high-quality evidence in this retrieval that tells you how to taper clozapine safely after decades of use. The 2018 note used gradual reduction, but it was not a controlled study. The rest of the retrieved studies are about other antipsychotics or about brain stimulation techniques that are not relevant here [2, 5, 7]. One case report describes neuroleptic malignant syndrome after abrupt clozapine withdrawal, which is a medical emergency [4]. That is the opposite of what you want.
My call: coming off clozapine after 25 years is possible in theory, but the evidence does not support a safe, reliable method. The risk of severe relapse is high, and the taper would need to be extremely slow, over many months or years, under close psychiatric supervision. Without a controlled trial or a large case series, no one can give you a protocol with confidence. Confidence: low.
Sources used 7
-
An attempt to discontinue clozapine – Worth a try?
A short, non-research clinical note describing six male patients on long-term clozapine who attempted dose reduction/discontinuation, noting short-term improvements in side effects but relapse of psychosis in some, necessitating dose-restoration and augmentation therapy with mix…
DOI: 10.1177/0004867418797433 -
Quetiapine for Schizophrenia
This rapid review found that clinical evidence did not clearly indicate which antipsychotic, including quetiapine, is better for schizophrenia; quetiapine was less effective than olanzapine, lurasidone, or clozapine in some populations but comparable to most others, with differi…
DOI: 10.51731/cjht.2025.1288 -
Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study
In a South Korean nationwide cohort of 44,396 first-episode schizophrenia patients, within-individual Cox models found LAI antipsychotics and LAI paliperidone lowest discontinuation risk, clozapine lowest psychiatric hospitalization risk among oral antipsychotics, and all antips…
DOI: 10.1017/s0033291721001379 -
Neuroleptic malignant syndrome and subsequent clozapine-withdrawal effects in a patient with refractory schizophrenia
This case report discusses a female patient with refractory schizophrenia who developed neuroleptic malignant syndrome after using clozapine and haloperidol, followed by withdrawal effects after abrupt discontinuation of clozapine.
DOI: 10.2147/NDT.S103687 -
P.413 Towards using EEG-Neurofeedback for the treatment of psychotic symptoms and working memory in schizophrenia: a feasibility study in healthy subjects
A multi-study report on neuromodulation therapies for treatment‑resistant psychiatric disorders, presenting long-term deep brain stimulation outcomes for treatment‑refractory depression, a feasibility assessment of EEG‑neurofeedback for schizophrenia‑related symptoms, and an RCT…
DOI: 10.1016/j.euroneuro.2020.09.306 -
Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity
This is a narrative review examining the pharmacokinetic and pharmacodynamic properties of antipsychotics in chronic schizophrenia with a focus on dopamine supersensitivity (DSP/Dopamine Supersensitivity Psychosis), and evaluating long-acting injectable antipsychotics, dopamine …
DOI: 10.1016/j.bbr.2021.113126 -
The Emerging Use of Brain Stimulation Treatments for Psychiatric Disorders
This paper provides a comprehensive review of current and emerging brain stimulation techniques for psychiatric disorders, detailing noninvasive methods (rTMS, tDCS, LFMS, T-PEMF, MST, FEAST, ECS) and invasive approaches (VNS, deep brain stimulation, DBS), evaluating their effic…
DOI: 10.3109/00048674.2011.615294